Mercuri, E. Et Al. 2022. Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Neurology , vol.21, no.1 , 42-52.

Mercuri, E., Deconinck, N., Mazzone, E. S., Nascimento, A., Oskoui, M., Saito, K., ... Vuillerot, C.(2022). Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial. The Lancet Neurology , vol.21, no.1, 42-52.

Mercuri, Eugenio Et Al. "Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial," The Lancet Neurology , vol.21, no.1, 42-52, 2022

Mercuri, Eugenio Et Al. "Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial." The Lancet Neurology , vol.21, no.1, pp.42-52, 2022

Mercuri, E. Et Al. (2022) . "Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial." The Lancet Neurology , vol.21, no.1, pp.42-52.

@article{article, author={Eugenio Mercuri Et Al. }, title={Safety and efficacy of once-daily risdiplam in type 2 and non-ambulant type 3 spinal muscular atrophy (SUNFISH part 2): a phase 3, double-blind, randomised, placebo-controlled trial}, journal={The Lancet Neurology}, year=2022, pages={42-52} }